Global Biosimilar Monoclonal Antibodies Market Growth 2025-2031

Global Biosimilar Monoclonal Antibodies Market Growth 2025-2031

The global Biosimilar Monoclonal Antibodies market size is predicted to grow from US$ 5955 million in 2025 to US$ 14960 million in 2031; it is expected to grow at a CAGR of 16.6% from 2025 to 2031.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent. In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

LP Information, Inc. (LPI) ' newest research report, the “Biosimilar Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Biosimilar Monoclonal Antibodies sales in 2024, providing a comprehensive analysis by region and market sector of projected Biosimilar Monoclonal Antibodies sales for 2025 through 2031. With Biosimilar Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Monoclonal Antibodies industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Monoclonal Antibodies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Monoclonal Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Monoclonal Antibodies.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other

Segmentation by Application:
Oncology
Autoimmune Disease
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Fresenius Kabi
Coherus Solutions
Biogen
Amgen
Biocon Biologics
Organon

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar Monoclonal Antibodies market?

What factors are driving Biosimilar Monoclonal Antibodies market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar Monoclonal Antibodies market opportunities vary by end market size?

How does Biosimilar Monoclonal Antibodies break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.